Fendi Dotcom Small

´╗┐Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock

Fendi Dotcom Small

Fendi Dotcom Small

Fendi Dotcom Small

Intercept Pharmaceuticals to Present at Deutsche Bank (DB) Healthcare Conference Why We Should Spend More on Pricey Cancer Drugs

Fendi Dotcom Small

Fendi Dotcom Small

Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial AbbVie (ABBV): We Can Win Race Fendi Monster Small Bag

Against Gilead Sciences, Inc. (GILD) for First Fendi Bag Collection

Fendi Dotcom Small

Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan Abbott Laboratories (ABT) Could Dominate Future Stent Marketplace, Analyst Claims

NEW YORK, June 17, 2013 /PRNewswire/ Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it has commenced an underwritten public offering of 1,730,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept.

Related News

BofA Merrill Lynch and Citigroup are Fendi Dotcom Small acting as joint book running managers, BMO Capital Markets is acting as lead manager and Needham Company, Wedbush PacGrow Life Sciences and Janney Montgomery Scott are acting as co managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Food and Drug Administration and European Medicines Agency; (iii) certain pre commercialization and potential commercial launch activities of OCA for PBC; and (iv) general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of its intellectual property.

New Hepatitis C Drugs

Fendi Dotcom Small

Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL Elan Corporation PLC (ELN) Boss Martin Faces Ownership Showdown, Elan Risks Losing $2 Billion if Royalty Pharma Walks

Fendi Dotcom Small

Intercept Pharmaceuticals to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 18 Restrictive Drug Laws Censor Science, Imperial College London and University of North Carolina Researchers Say

Fendi Dotcom Small

year ended December 31, 2012, our quarterly report on Form 10 Q for the quarter ended March 31, 2013, and in the preliminary prospectus related to the proposed offering filed with the Securities and Exchange Commission on the date of this press release, as well as any updates to these risk factors filed from time to time in Intercept's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intercept undertakes no duty to update this information unless required by law.

Fendi Dotcom Small

A registration statement on Form S 1 relating to the public offering of the shares of common stock described above has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first in class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. These risks and uncertainties include, but are not limited to: whether or not we will be able to raise capital through the sale of shares of common stock; the final terms of the proposed offering; Intercept's use of the proceeds from this offering and its recently completed initial public offering; the satisfaction of customary closing conditions related to the proposed public offering; the initiation, cost, timing, progress and results of Intercept's development activities, preclinical studies and clinical trials; the timing of and Intercept's ability to obtain and maintain regulatory approval of OCA and any other product candidates it may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; Intercept's plans to research, develop and commercialize future product candidates; the election by Intercept's collaborators to pursue research, development and commercialization activities; Intercept's ability to attract collaborators with development, regulatory and commercialization expertise; Intercept's ability to obtain and maintain intellectual property protection for its product candidates; Intercept's ability to successfully commercialize its product candidates; the size and growth of the markets for Intercept's product candidates and its ability to serve those markets; the rate and degree of market acceptance of any future products; the success of competing drugs that are or become available; regulatory developments in the United States and other countries; the performance of third party suppliers and manufacturers; Intercept's ability to obtain additional financing; the accuracy of Intercept's estimates regarding expenses, future revenues, capital requirements and the need for additional financing; the loss of key scientific or management personnel; and other factors discussed under the heading "Risk Factors" contained in Intercept's annual report on Form 10 K for the Fendi Handbag Monster

Fendi Dotcom Small

Fendi Roma Bags

Fendi Bag Online

Handbags Burberry 2015
Burberry Bags Red
Fendi Handbags Latest Collection

Burberry London Crossbody Briefcase
Fendi Tote Eyes

Burberry Phone Case Galaxy S6
Fendi Iphone Case Nordstrom

Fendi Peekaboo Price

Fendi Dotcom Size

Monster Backpack Fendi Replica

Fendi Monogram Wallet

Fendi Purse Eyes

Burberry Iphone 8 Plus Case

Home / Fendi Dotcom Small